Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Determining the Safety of CAR T-Cell Therapy for Lymphoma

13 de noviembre de 2026 actualizado por: University of Chicago

Phase I Dose-Escalation/Expansion Study of Anti-CD19/CD22 CAR T-Cell Therapy for Relapsed/Refractory Mature B-cell Lymphoma After Prior CD19 CAR T-Cell Failure

This study seeks to determine the safety of CAR T-cell therapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

Descripción general del estudio

Descripción detallada

This study seeks to determine the safety of CAR T-cell therapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

When non-Hodgkin lymphoma returns (relapses) or stops responding to treatment (refractory), standard options like chemotherapy or common targeted drugs can become ineffective. This study evaluates a treatment approach called CAR T-cell therapy. CAR T-cell therapy uses a participant's own immune cells (T cells) to hunt down and fight cancer.

Participants in this study will first have their T cells collected through a process called leukapheresis, where blood is drawn, spun through a machine to filter out T cells, and the remaining blood is returned to the body. In the laboratory, these T cells are modified with a Chimeric Antigen Receptor (CAR) protein, which acts like a targeting system to help the T cells recognize two specific markers on lymphoma cells: Cluster of Differentiation 19 (CD19) and Cluster of Differentiation 22 (CD22). The modified CAR T-cells are then given back to the participant through an intravenous (IV) infusion.

The main goal of this study is to find the safest and most effective dose of anti-CD19/CD22 CAR T-cells without causing unexpected or severe side effects. The study also evaluates how the body reacts to the treatment and measures how well the therapy works at shrinking or eliminating the cancer.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

36

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • The University of Chicago Medicine Comprehensive Cancer Center
        • Contacto:
        • Investigador principal:
          • Alexandra E. Rojek, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2
  • At least 1 measurable lesion according to the Lugano Response Criteria for Malignant Lymphoma70
  • Measurable disease defined as ≥ 1 measurable nodal lesion (long axis > 1.5 cm and short axis > 1.0 cm) or ≥ 1 measurable extranodal lesion (long axis > 1.0 cm) on computed tomography (CT) or magnetic resonance imaging (MRI)
  • Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy
  • Total bilirubin ≤ 2.0 mg/dL (or < 3.0 mg/dL for subjects with Gilbert's syndrome or lymphomatous infiltration of the liver)
  • Alanine aminotransferase (AST) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN); or ≤ 5 x ULN if known lymphomatous infiltration of the liver
  • Creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min
  • Adequate cardiac function as defined by left ventricular ejection fraction (LVEF) ≥ 40% as assessed by echocardiography, multigated acquisition scan (MUGA), or cardiac MRI
  • Baseline oxygen saturation ≥ 92% on room air
  • Adequate bone marrow function without growth factor support with short-acting G-CSF within the previous 7 days or long-acting G-CSF within the previous 14 days, and without transfusion support within 7 days prior to apheresis:
  • Absolute neutrophil count (ANC) ≥ 1,000/microliter (µL)
  • Absolute lymphocyte count (ALC) ≥ 100/microliter (µL)
  • Platelets ≥ 50,000/microliter (µL)
  • Hemoglobin ≥ 7g/dL
  • Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • The presence of any of the following will exclude a subject from study enrollment:
  • Presence of acute or extensive chronic graft versus host disease (GVHD).
  • Active central nervous system or meningeal involvement by lymphoma. Subjects with untreated brain metastases/central nervous system (CNS) disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of CNS or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced MRI imaging for at least 90 days prior to registration.
  • History of another primary malignancy that has not been in remission for at least 2 years. The following are examples of exemptions from the 2-year limit: nonmelanoma skin cancer, definitively treated stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou (PAP) smear, and in situ breast cancer that has been completely resected.
  • HIV seropositivity.
  • Subjects with uncontrolled intercurrent illness.
  • Pregnant or breastfeeding women are excluded from this study because CAR T-cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of childbearing potential must have a negative serum pregnancy test. Subjects of either sex who are not willing to practice birth control from the time of consent and at least 6 months after protocol-directed CAR T-cell infusion are excluded (see Section 9.6 for contraception method). Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR T-cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study.
  • Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)
  • Presence of an active and clinically relevant CNS disorder such as epilepsy, generalized seizure disorders, paresis, aphasia, stroke, uncontrolled cerebrovascular disease, cerebellar disease, severe brain injuries, dementia and Parkinson's disease
  • History of autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.
  • Patients who have received >1 prior CAR T-cell infusion. Patients treated with multiple CAR T-cell infusions in the context of a prior prospective therapeutic clinical trial will be permitted.
  • Any medical condition likely to interfere with assessment of safety or efficacy of study treatment
  • History of severe immediate hypersensitivity reaction to tocilizumab, anakinra or any of the agents used in this study
  • Major surgery within 28 days prior to start of lymphodepleting chemotherapy or any planned medical/surgical treatment that might interfere with the ability to comply with the study requirements.
  • Patients must have a washout period of at least 2 weeks or 5 half-lives, whichever is shorter, since any prior cancer therapy, at the time the patient undergoes apheresis, except as follows:
  • Treatment with alemtuzumab or bendamustine within 6 months of apheresis, or treatment with fludarabine, melphalan, or cladribine within 3 months of apheresis
  • Allogeneic hematopoietic stem cell transplant within 12 weeks prior to apheresis
  • Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 5 days prior to apheresis. Physiologic replacement, topical, and inhaled steroids are permitted.
  • Oral targeted agents, including lenalidomide and ibrutinib, are allowed if at least 3 half-lives have elapsed prior to apheresis.
  • Experimental agents within 4 weeks of apheresis unless no response or disease progression is documented on the experimental therapy and at least 3 half-lives have elapsed prior to apheresis
  • Radiation within 6 weeks of apheresis. Subjects must have progressive disease in irradiated lesions or have additional non-irradiated, PET-positive lesions to be eligible. Radiation to a single lesion or lesions, if additional non-irradiated PET-positive lesions are present, is allowed up to 2 weeks prior to apheresis.
  • Prior cell, gene, or antibody-based therapy (approved or investigational) targeting both cluster of differentiation 19 (CD19) and cluster of differentiation 22 (CD22).
  • Prior bispecific T-cell engaging antibody therapy targeting cluster of differentiation 20 (CD20), cluster of differentiation 19 (CD19), or cluster of differentiation 22 (CD22) on B-cells: a minimum of 30 days must have elapsed between the last dose of bispecific T-cell engaging antibody therapy and apheresis.
  • CD19-directed CAR T-cell infusion within 12 weeks of planned apheresis.
  • Prior cell, gene, or antibody-based therapy (approved or investigational) targeting both CD19 and CD22.
  • Prior bispecific T-cell engaging antibody therapy targeting CD20, CD19, or CD22 on B-cells: a minimum of 30 days must have elapsed between the last dose of bispecific T-cell engaging antibody therapy and apheresis.
  • CNS prophylaxis (e.g., intrathecal methotrexate): must be stopped at least 1 week prior to apheresis
  • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2 [IL-2]) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to apheresis.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Dose-Finding (Dose Escalation) Group

This group is part of the dose-finding phase of the study. The goal of this phase is to find the safest and most effective dose of CAR T-cell therapy with the fewest side effects.

Participants in this group will first receive lymphodepleting chemotherapy with fludarabine (30 mg/day) and cyclophosphamide (300 mg/day) daily for 3 days (given 5 to 3 days before the T-cell infusion).

After completing chemotherapy, participants will receive a single infusion of CAR-positive T-cells. They will receive 1 of 4 dose levels of CAR T-Cells based on when they join the study and side effects to each dose level. Up to 18 participants will be in this group.

  • Dose Level -1 (Lowered Dose): 5 x 10^5 cells/kg (500,000 cells/kg) given as a single intravenous (IV) infusion. Dose level -1 is a lowered dose that will be given if participants have serious side effects to the starting dose (dose level 1).
  • Dose Level 1 (Starting Dose): 1 x 10^6 cells/kg (1,000,000 cells/kg) given as a single intravenous (IV) infusion
  • Dose Level 2: 2 x 10^6 cells/kg (2,000,000 cells/kg) given as a single intravenous (IV) infusion
  • Dose Level 3: 3 x 10^6 cells/kg (3,000,000 cells/kg) given as a single intravenous (IV) infusion
Otros nombres:
  • CAR T-Cell Therapy, T-Cell Therapy

Fludarabine: 30 mg will be given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The fludarabine dose remains the same (30 mg) across all dose levels (Level -1 through Level 3).

Otros nombres:
  • Fludara
  • fosfato de fludarabina

Cyclophosphamide: 300 mg given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The cyclophosphamide dose remains the same (300 mg) across all dose levels (Level -1 through Level 3).

Otros nombres:
  • Citoxano
  • Neosar
Experimental: Dose Expansion Group

This group is part of the dose expansion phase of the study. The goal of this phase is to further test the dose of CAR T-cell therapy that was selected during the dose-finding phase.

Participants in this group will first receive chemotherapy with fludarabine (30 mg/day) and cyclophosphamide (300 mg/day) daily for 3 days (given 5 to 3 days before the T-cell infusion).

After completing chemotherapy, participants will receive a single infusion of CAR-positive T-cells at the selected dose. Up to 36 participants will be in this group.

  • Dose Level -1 (Lowered Dose): 5 x 10^5 cells/kg (500,000 cells/kg) given as a single intravenous (IV) infusion. Dose level -1 is a lowered dose that will be given if participants have serious side effects to the starting dose (dose level 1).
  • Dose Level 1 (Starting Dose): 1 x 10^6 cells/kg (1,000,000 cells/kg) given as a single intravenous (IV) infusion
  • Dose Level 2: 2 x 10^6 cells/kg (2,000,000 cells/kg) given as a single intravenous (IV) infusion
  • Dose Level 3: 3 x 10^6 cells/kg (3,000,000 cells/kg) given as a single intravenous (IV) infusion
Otros nombres:
  • CAR T-Cell Therapy, T-Cell Therapy

Fludarabine: 30 mg will be given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The fludarabine dose remains the same (30 mg) across all dose levels (Level -1 through Level 3).

Otros nombres:
  • Fludara
  • fosfato de fludarabina

Cyclophosphamide: 300 mg given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The cyclophosphamide dose remains the same (300 mg) across all dose levels (Level -1 through Level 3).

Otros nombres:
  • Citoxano
  • Neosar

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safe Dose Level (Recommended Phase 2 Dose)
Periodo de tiempo: Day 30 after CAR T-cell infusion

To find the safest dose of anti-CD19/22 CAR T-cells as assessed by tracking severe side effects (dose-limiting toxicities) during the first month after treatment.

Day 30 after CAR T-cell infusion

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety Profile of Anti-CD19/CD22 CAR T-cells
Periodo de tiempo: First day of CAR T-cell infusion (Day 0) through 12 months after infusion

To describe the safety profile related to the infusion of anti-CD19/CD22 CAR T-cells, evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.

First day of CAR T-cell infusion (Day 0) through 12 months after infusion
Severity of Toxicities Related to Treatment with Anti-CD19/CD22 CAR T-cells
Periodo de tiempo: First day of CAR T-Cell infusion (Day 0) through 12 months after infusion

To record the severity of toxicities (side effects) related to the infusion of anti-CD19/CD22 CAR T-cells, evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.

First day of CAR T-Cell infusion (Day 0) through 12 months after infusion
Percentage of Participants with Overall Response Rate
Periodo de tiempo: Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion

The percentage of participants whose cancer shrinks or completely disappears (complete response) following CAR T-cell treatment as assessed by standard disease response criteria for lymphoma (PET-CT imaging and clinical response assessments).

Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion
Percentage of Participants with Complete Response Rate
Periodo de tiempo: Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion

The percentage of participants who show a complete disappearance of all signs of cancer (complete response) following CAR T-cell treatment as assessed by standard disease response criteria for lymphoma (PET-CT imaging and clinical response assessments).

Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Alexandra E. Rojek, MD, University of Chicago

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

13 de julio de 2027

Finalización primaria (Estimado)

29 de octubre de 2031

Finalización del estudio (Estimado)

29 de octubre de 2031

Fechas de registro del estudio

Enviado por primera vez

13 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Publicado por primera vez (Actual)

19 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir